Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glucagon
promotes hepatic glucose production maintaining glucose homeostasis in the fasting state.
Glucagon
maintains at high level in both diabetic animals and human, contributing to hyperglycemia. Mitochondria, a major place for glucose oxidation, are dysfunctional in diabetic condition. However, whether hepatic mitochondrial function can be affected by
glucagon
remains unknown. Recently, we reported that FOXO1 is an important mediator in
glucagon
signaling in control of glucose homeostasis. In this study, we further assessed the role of FOXO1 in the action of
glucagon
in the regulation of hepatic mitochondrial function. We found that
glucagon
decreased the heme production in a FOXO1-dependent manner, suppressed heme-dependent complex III (
UQCRC1
) and complex IV (MT-CO1) and inhibited hepatic mitochondrial function. However, the suppression of mitochondrial function by
glucagon
was largely rescued by deleting the Foxo1 gene in hepatocytes.
Glucagon
tends to reduce hepatic mitochondrial biogenesis by attenuating the expression of NRF1, TFAM and MFN2, which is mediated by FOXO1. In db/db mice, we found that hepatic mitochondrial function was suppressed and expression levels of
UQCRC1
, MT-CO1, NRF1 and TFAM were downregulated in the liver. These findings suggest that hepatic mitochondrial function can be impaired when hyperglucagonemia occurs in the patients with diabetes mellitus, resulting in organ failure.
...
PMID:Glucagon regulates hepatic mitochondrial function and biogenesis through FOXO1. 3102 11